Influenza vaccines based on virus-like particles
- PMID: 19374929
- PMCID: PMC2753524
- DOI: 10.1016/j.virusres.2009.04.005
Influenza vaccines based on virus-like particles
Abstract
The simultaneous expression of structural proteins of virus can produce virus-like particles (VLPs) by a self-assembly process in a viral life cycle even in the absence of genomic material. Taking an advantage of structural and morphological similarities of VLPs to native virions, VLPs have been suggested as a promising platform for new viral vaccines. In the light of a pandemic threat, influenza VLPs have been recently developed as a new generation of non-egg based cell culture-derived vaccine candidates against influenza infection. Animals vaccinated with VLPs containing hemagglutinin (HA) or HA and neuraminidase (NA) were protected from morbidity and mortality resulting from lethal influenza infections. Influenza VLPs serve as an excellent model system of an enveloped virus for understanding the properties of VLPs in inducing protective immunity. In this review, we briefly describe the characteristics of influenza VLPs assembled with a lipid bilayer containing glycoproteins, and summarize the current progress on influenza VLPs as an alternative vaccine candidate against seasonal as well as pandemic influenza viruses. In addition, the protective immune correlates induced by vaccination with influenza VLPs are discussed.
Similar articles
-
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.Vaccine. 2012 May 14;30(23):3413-22. doi: 10.1016/j.vaccine.2012.03.033. Epub 2012 Mar 29. Vaccine. 2012. PMID: 22465746
-
Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.Vaccine. 2016 Jun 17;34(29):3371-80. doi: 10.1016/j.vaccine.2016.04.089. Epub 2016 May 5. Vaccine. 2016. PMID: 27155499
-
Influenza virus-like particle vaccines.Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8. Expert Rev Vaccines. 2009. PMID: 19348559 Review.
-
Influenza virus-like particles as pandemic vaccines.Curr Top Microbiol Immunol. 2009;333:269-89. doi: 10.1007/978-3-540-92165-3_14. Curr Top Microbiol Immunol. 2009. PMID: 19768411 Review.
-
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.Clin Vaccine Immunol. 2011 Dec;18(12):2010-7. doi: 10.1128/CVI.05206-11. Epub 2011 Oct 26. Clin Vaccine Immunol. 2011. PMID: 22030367 Free PMC article.
Cited by
-
Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.Virol J. 2013 May 4;10:141. doi: 10.1186/1743-422X-10-141. Virol J. 2013. PMID: 23642219 Free PMC article. Review.
-
Plant-derived virus-like particles as vaccines.Hum Vaccin Immunother. 2013 Jan;9(1):26-49. doi: 10.4161/hv.22218. Epub 2012 Sep 20. Hum Vaccin Immunother. 2013. PMID: 22995837 Free PMC article. Review.
-
Virus like particle-based vaccines against emerging infectious disease viruses.Virol Sin. 2016 Aug;31(4):279-87. doi: 10.1007/s12250-016-3756-y. Epub 2016 Jul 11. Virol Sin. 2016. PMID: 27405928 Free PMC article. Review.
-
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Rev Med Virol. 2012 Jul;22(4):267-79. doi: 10.1002/rmv.1713. Epub 2012 Mar 22. Rev Med Virol. 2012. PMID: 22438243 Free PMC article. Review.
-
Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy.Influenza Other Respir Viruses. 2013 May;7(3):340-8. doi: 10.1111/j.1750-2659.2012.00396.x. Epub 2012 Jun 21. Influenza Other Respir Viruses. 2013. PMID: 22716302 Free PMC article.
References
-
- Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 1999;18(1–2):57–67. - PubMed
-
- Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. Vaccine 2008 - PubMed
-
- Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical